Planned maintenance

We must perform activities that will impact the ability to place orders on our website. Starting Friday, May 21, at 5:00 p.m. Eastern to Sunday, May 23, at 5:00 p.m. Eastern, you will not be able to order products on our website. You will still be able to browse and access your account. We apologize for any inconvenience this work may cause.

Epithelial-mesenchymal Transition

Epithelial-mesenchymal transition (EMT) and its reverse, mesenchymal-epithelial transition (MET), are developmental programs that have been shown to play critical roles in promoting metastasis and invasion as well as contribute to drug resistance in carcinoma. ATCC has employed CRISPR/Cas9 gene editing to develop new reporter lines designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal. 

  • CRISPR/Cas9 gene-edited vimentin-RFP fusion protein
  • Strong RFP signal upon vimentin induction
  • Physiological E-cadherin expression in absence of EMT
  • Lung or colon models currently available
  • Increased invasive capacity following EMT
  • TGFβ1-responsive (lung model)
  • Sensitive to A83-01 and PP1 inhibition (lung model)
  • miR-200 family inhibitor-responsive (colon model)

  • Scientific Paper: Live-cell imaging and analysis reveal cell phenotypic transition dynamics inherently missing in snapshot data

    Recent advances in single-cell techniques allow for the study of how cells convert from epithelial to mesenchymal phenotypes. This research paper describes a live-cell imaging platform that tracks cellular status change through combining endogenous fluorescent labeling and live-cell imaging of high-dimensional cell morphological and texture features. With this platform and A549 VIM-RFP epithelial-to-mesenchymal transition (EMT) reporter cell line (ATCC® CCL-185EMT™), live-cell imaging of EMT is possible. Read this recent Science Advances article to appreciate the phenotypic transitions captured from multiplex live-cell imaging.

    Fluorescence-labeled EMT Reporter

    Validation of A549-Vim-RFP

    Upon EMT induction, the EMT reporter cell line undergoes morphological changes from epithelial to mesenchymal and demonstrates increased expression of Vim-RFP. Learn more about how ATCC created and validated these advanced EMT models from the flyer.

    EMT/MET Reporter Cells

    BT-474 ECAD-EmGFP Cell Line
    MCF 10A ECAD EmGFP Cell Line

    By utilizing the CRISPR/Cas9 gene editing, ATCC offers advanced EMT models of lung, breast, and colon carcinoma and an MET model of breast and pancreatic cancer. These cell lines serve as ideal in vitro models for metastasis studies and anti-cancer drug screening.

    Related Products

    A549 cells
    BT-474 cells
    HCT116 cells
    F12K Medium
    McCoy’s 5A Medium
    Fetal Bovine Serum

    ATCC can provide the basal culture medium and serum that you need to grow your EMT and MET cells. We also carry the parental A549, BT-474, HCT116, and MDA-MB-231 cell lines.